Balversa FDA Approval History
FDA Approved: Yes (First approved April 12, 2019)
Brand name: Balversa
Generic name: erdafitinib
Dosage form: Tablets
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Urothelial Carcinoma
Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.
Development timeline for Balversa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.